Business Context and Reporting Period
Protagonist Therapeutics, Inc. (PTGX) filed this Form 8-K on March 10, 2023, to address the current situation affecting Silicon Valley Bank (SVB) under Item 7.01 Regulation FD Disclosure.
Key Financial Metrics
- Cash at SVB: Approximately $13 million as of March 9, 2023.
- Third-Party Investments: Approximately $218 million held with multiple institutions, not directly exposed to SVB.
- Other Metrics: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or debt.
Material Changes
The filing does not report material changes to financial performance versus prior periods. It specifically addresses the company's exposure to the SVB liquidity event.
Outlook, Risks, and Management Commentary
Management states that Protagonist considers its exposure to any liquidity concern at SVB to be limited. The company notes that while it holds cash at SVB, the majority of its third-party investments are custodied by multiple other institutions and are not directly exposed to SVB consequences.
Investor Verification Checklist
- Verify the exact amount of cash held at SVB as of the most recent date.
- Confirm the status of the $218 million in third-party investments and their custodians.
- Monitor for any updates regarding the withdrawal or freezing of the $13 million SVB deposit.